Screening of novel chemical compounds as possible inhibitors of carbonic anhydrase and photosynthetic activity of photosystem II

Thirty novel chemical compounds were designed and synthesized expecting that they would be possible inhibitors. From this number eleven were organic bases, twenty-four were their organic derivatives and fourteen were metal complexes. Screening of these chemicals by their action on photosynthetic electron transfer (PET) and carbonic anhydrase (CA) activity (CAA) of photosystem II (PSII), α-CA, as well as β-CA was done. Several groups were revealed among them. Some of them are capable to suppress either one, two, three, or even all of the measured activities. As example, one of the Cu(II)-phenyl sulfonylhydrazone complexes (compound 25) suppresses CAA of α-CA by 88%, CAA of β-CA by 100% inhibition; CAA of PSII by 100% and the PSII photosynthetic activity by 66.2%. The Schiff base compounds (12, 15) and Cu(II)-phenyl sulfonylhydrazone complexes (25, 26) inhibited the CAA and PET of PSII significantly. The obtained data indicate that the PSII donor side is a target of the inhibitory action of these agents. Some physico- or electrochemical properties such as diffusion coefficient, number of transferred electrons, peak potential and heterogeneous standard rate constants of the compounds were determined in nonaqueous media. pKa values were also determined in nonaqueous and aqueous media. Availability in the studied group of novel chemical agents possessing different inhibitory activity allow in future to isolate the "active part" in the structure of the inhibitors responsible for different inhibitory mechanisms, as well as to determine the influence of side substituters on its inhibitory efficiency.

POS0851 FREQUENCY OF METABOLIC SYNDROME AND ITS RELATIONSHIP WITH DISEASE CHARACTERISTICS IN PATIENTS WITH SYSTEMIC SCLEROSIS

Background

Although the frequency of metabolic syndrome (MetS) has been found to increase in many rheumatological diseases such as rheumatoid arthritis, systemic lupus erythematosus, few studies have been conducted on the frequency of MetS in systemic sclerosis (SSc), and the results are inconsistent.

Objectives

In our study, we aimed to investigate the frequency of MetS in patients with SSc and its relationship with disease characteristics including organ involvement.

Methods

In a cross-sectional, single-center study, 76 patients who applied to our outpatient clinic between July and September 2021 were included in the study. MetS diagnoses were determined according to anthropometric measurements, lipid parameters, blood pressures, and NCEP ATP 3 criteria, and its relationship with SSc end-organ involvement and disease characteristics was examined.

Results

MetS was detected in 37 (48.7%) of 76 patients. Systolic and diastolic blood pressure, waist circumference, height, body mass index, LDL, triglyceride, and fasting blood glucose mean were found to be statistically significantly higher in patients with MetS (p<0.05). In addition, HDL was found to be significantly lower in patients with MetS diagnosis than in patients without MetS (p<0.05). While no significant relationship was found between MetS and SSc end-organ involvement, SSc disease activities (RAI, SCTC-DI), disease duration, a significant statistical relationship was found between MetS and modified Rodnan skin score (mRSS). It was found that patients with MetS had lower mRSS (p:0.019). According to ROC analysis, the mRSS cut-off point that predicting the presence of MetS was mRSS ≤11 (specificity: 84%, sensitivity: 45.95%, AUC: 0.656, p: 0.014). No statistically significant correlation was found in the comparison with MetS risk factors for mRSS ≤11.

Conclusion

In our study, the frequency of MetS in patients with SSc was found to be lower than in the same age group in Turkey MetS prevalence studies. The frequency of Mets in our study is thought to be due to age and gender dominance rather than SSc itself. Although mRSS was found to be significantly lower in patients with MetS, its sensitivity to predict MetS was found to be low. MetS is less common in patients with high mRSS; It is thought that cachexia due to inflammation, loss of appetite, and malnutrition due to GI involvement may have been effective.

References

[1]Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–52.

[2]Metabolic syndrome, autoimmunity and rheumatic diseases. Pharmacol Res.2018;133:277–88.

[3]Frequency of Metabolic Syndrome in Female Patients with Systemic Sclerosis: A Preliminary Report. Jrd. 2012;19(5):262–9.

[4]Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis. Clin Rheumatol. 2021 Oct;40(10):4253-4258

[5]Prevalence of metabolic syndrome and insulin resistance in system sclerosis. Rev Med Inst Mex Seguro Soc. 2015;53(4):476–83.

[6]Serum adipokines levels in patients with systemic sclerosis: A meta-analysis. Mod Rheumatol. 2017;27(2):298–305.

Disclosure of Interests

None declared